PEL.NS

Piramal Enterprises Limited [PEL.NS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PEL.NS Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

The Moving Average Convergence Divergence (MACD) for PEL.NS recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (0.66%) are lower than the previous year (3%)

PEL.NS has less than 1 year of cash runway

Top 10 Correlated ETFs

PEL.NS

Top 10 Correlated Stocks

PEL.NS

In the News

PEL.NS Financial details

Company Rating

Neutral

Market Cap

192.99B

Income

-18.78B

Revenue

61.17B

Book val./share

Cash/share

Dividend

Dividend %

3.36%

Employees

12.22K

Optionable

Shortable

Yes

Earnings

03 May 2024

P/E

5.41

Forward P/E

PEG

-0.26

P/S

3.4

P/B

0.76

P/C

P/FCF

345102.63

Quick Ratio

3.87

Current Ratio

56.69

Debt / Equity

LT Debt / Equity

EPS (TTM)

-85.33

EPS next Y

EPS next Q

EPS this Y

647.86%

EPS next Y

EPS next 5Y

EPS last 5Y

52.79%

Revenue last 5Y

-18.29%

Revenue Q/Q

9.37%

EPS Q/Q

-5340.89%

SMA20

-0.35%

SMA50

-3.71%

SMA100

-10.37%

Inst Own

Inst Trans

ROA

ROE

14%

ROC

0.08%

Gross Margin

89%

Oper. Margin

100%

Profit Margin

66%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

696.55-1139.95

52W High

-26.15%

52W Low

+20.86%

RSI

Rel Volume

0.48

Avg Volume

1.36M

Volume

650.38K

Perf Week

-1.27%

Perf Month

-10.09%

Perf Quarter

-17.63%

Perf Half Y

-20.39%

Beta

0.772

Volatility

16.81%, 34.62%

Prev Close

0.44%

Price

841.2

Change

0.99%

PEL.NS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	646.57	615.32	538.56	580.35	201.49
Net income per share	72.49	1.14	56.19	80.7	603.52
Operating cash flow per share	-570.73	356.61	154.54	367.18	57.24
Free cash flow per share	-604.78	334.28	129.44	326.96	48.71
Cash per share	162.83	390.33	429.44	455.75	195.75
Book value per share	1.34K	1.45K	1.43K	1.49K	1.31K
Tangible book value per share	897.03	1.26K	1.32K	1.35K	1.29K
Share holders equity per share	1.34K	1.45K	1.43K	1.49K	1.31K
Interest debt per share	2.97K	2.24K	1.84K	2.53K	2.78K
Market cap	310.42B	115.05B	241.53B	302.77B	161.11B
Enterprise value	862.6B	494.02B	579.91B	795.4B	618.92B
P/E ratio	21.07	478.78	18.13	15.74	1.12
Price to sales ratio	2.36	0.89	1.89	2.19	3.37
POCF ratio	-2.68	1.53	6.59	3.46	11.85
PFCF ratio	-2.53	1.63	7.87	3.89	13.93
P/B Ratio	1.14	0.38	0.71	0.85	0.52
PTB ratio	1.14	0.38	0.71	0.85	0.52
EV to sales	6.57	3.81	4.54	5.75	12.93
Enterprise value over EBITDA	11.83	6.94	7.34	9.97	13.43
EV to operating cash flow	-7.44	6.57	15.83	9.09	45.53
EV to free cash flow	-7.02	7.01	18.89	10.21	53.51
Earnings yield	0.05	0	0.06	0.06	0.89
Free cash flow yield	-0.4	0.61	0.13	0.26	0.07
Debt to equity	2.06	1.38	1.16	1.57	2.1
Debt to assets	0.65	0.56	0.51	0.56	0.01
Net debt to EBITDA	7.57	5.32	4.28	6.18	9.94
Current ratio	0.39	0.68	1.49	1.3	3.9K
Interest coverage	1.56	1.17	1.69	1.45	6.3
Income quality	-4.68	9.27	1.2	4.32	-0.55
Dividend Yield	0.01	0.05	0.01	0.03	0.05
Payout ratio	0.3	23.17	0.24	0.41	0.05
Sales general and administrative to revenue	0.02	0.02	0.03	0.04	0.13
Research and developement to revenue	0.02	0.01	0.01	0.01	0
Intangibles to total assets	0.11	0.05	0.05	0.05	0
Capex to operating cash flow	0.06	-0.06	-0.16	-0.11	-0.15
Capex to revenue	-0.05	-0.04	-0.05	-0.07	-0.04
Capex to depreciation	-1.33	-0.71	-1.06	-1.44	-1.65
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.48K	192.89	1.35K	1.64K	4.21K
ROIC	0.05	-0.03	0.04	0.06	0.05
Return on tangible assets	0.02	0	0.02	0.02	0
Graham Net	-2.39K	-1.45K	-1.05K	-1.79K	-195.39K
Working capital	-188.07B	-75.6B	65.2B	56.13B	46467.82B
Tangible asset value	182.28B	265.2B	312.68B	321.64B	306.57B
Net current asset value	-460.9B	-282.24B	-221.12B	-387.24B	22.13B
Invested capital	2.06	1.38	1.16	1.57	2.1
Average receivables	57.56B	73.83B	74.43B	99.9B	63.09B
Average payables	9.16B	9.74B	10.84B	14.38B	10.48B
Average inventory	8.05B	9.48B	11.8B	14.16B	7.67B
Days sales outstanding	224.95	187.7	234.84	310.47	65.21
Days payables outstanding	200.74	191.55	117.66	218.3	8.06K
Days of inventory on hand	175.13	205.35	129.7	197.27	0
Receivables turnover	1.62	1.94	1.55	1.18	5.6
Payables turnover	1.82	1.91	3.1	1.67	0.05
Inventory turnover	2.08	1.78	2.81	1.85	0
ROE	0.05	0	0.04	0.05	0.46
Capex per share	-34.05	-22.33	-25.1	-40.22	-8.53

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	87.73	7.6	79.74	81.33	94.48
Net income per share	148.55	-2.39	21.42	2.03	-106.39
Operating cash flow per share	2.54	0	3.13	3.22	3.7
Free cash flow per share	2.54	0	3.13	3.22	3.7
Cash per share	252.74	195.75	0	164.97	0
Book value per share	1.31K	1.31K	1.31K	1.21K	0
Tangible book value per share	0	1.29K	0	1.2K	0
Share holders equity per share	1.31K	1.31K	1.31K	1.21K	0
Interest debt per share	2K	2.76K	43.6	2.14K	49.34
Market cap	197.71B	161.11B	223.79B	249.1B	208.78B
Enterprise value	604.48B	618.92B	223.79B	719.13B	208.78B
P/E ratio	1.39	-70.81	11	129.23	-2.2
Price to sales ratio	9.44	89.24	11.82	12.9	9.89
POCF ratio	325.82	268.51K	300.8	325.46	252.27
PFCF ratio	325.82	268.51K	300.8	325.46	252.27
P/B Ratio	0.63	0.52	0.72	0.87	0
PTB ratio	0.63	0.52	0.72	0.87	0
EV to sales	28.87	342.84	11.82	37.25	9.89
Enterprise value over EBITDA	36.39	529.86	6.91	59.91	15.48
EV to operating cash flow	996.18	1.03M	300.8	939.55	252.27
EV to free cash flow	996.18	1.03M	300.8	939.55	252.27
Earnings yield	0.18	0	0.02	0	-0.11
Free cash flow yield	0	0	0	0	0
Debt to equity	1.5	2.1	0	1.73	0
Debt to assets	0.6	0.01	0	0.61	0
Net debt to EBITDA	24.49	391.93	0	39.15	0
Current ratio	0.13	3.9K	0	56.69	0
Interest coverage	1.7	0.69	3.09	1.12	1.19
Income quality	0.02	0	0.15	1.59	-0.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	1.57	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.09K	265.47	793.95	235.03	0
ROIC	0.65	0.01	0.08	0.01	0
Return on tangible assets	0.05	0	0	0	0
Graham Net	-3.01K	-195.39K	0	-2.06K	0
Working capital	-406.77B	46467.82B	0	563.64B	0
Tangible asset value	0	306.57B	0	285.33B	0
Net current asset value	-719.18B	22.13B	0	44.41B	0
Invested capital	1.5	2.1	0	1.73	0
Average receivables	116.9M	4.27B	4.27B	187.2M	187.2M
Average payables	3.19B	2B	2B	2.17B	2.17B
Average inventory	-116.9M	0	0	0	0
Days sales outstanding	0	426.22	0	1.75	0
Days payables outstanding	0	17.61K	0	105.62	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0.21	0	51.57	0
Payables turnover	0	0.01	0	0.85	0
Inventory turnover	0	0	0	0	0
ROE	0.11	0	0.02	0	0
Capex per share	0	0	0	0	0

PEL.NS Dividend History

PEL.NS Frequently Asked Questions

What is Piramal Enterprises Limited stock symbol ?

Piramal Enterprises Limited is a IN stock and trading under the symbol PEL.NS

What is Piramal Enterprises Limited stock quote today ?

Piramal Enterprises Limited stock price is $841.2 today.

Is Piramal Enterprises Limited stock public?

Yes, Piramal Enterprises Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.36M
Market Capitalization 192.99B
Employee 12.22K
CEO Mr. Yesh Nadkarni
Headquarters Mumbai,IN
IPO Date 1996-01-02
Website https://www.piramal.com/businesses/piramal-enterprises/

Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.